MacroGenics is betting its antibody platform can open up new options for hard-to-treat cancers, with upcoming studies that could attract partners or even a buyout. But the story hinges on clinical wins and deals landing on time, while losses and rising trial costs could force tough choices.Read more
MacroGenics is chasing new cancer treatments, but it’s still burning a lot of cash and now leans heavily on deals and one-off payments instead of steady product sales. See why delays in trials or approvals—and tougher competition—could keep the business from turning promising science into reliable growth.Read more
MacroGenics is pushing ahead with several cancer drug trials that could unlock new treatments if the results hold up, and the next round of updates may reshape what investors expect from the business. But rising research spending and a limited cash runway mean the company may need a partner or new funding sooner than many realize.Read more
No trending discussion available.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
